Ionis Pharma (IONS) Stock Forecast & Price Target

Ionis Pharmaceuticals is viewed favorably because its diversified antisense pipeline is translating into tangible late-stage wins, highlighted by sefaxersen’s Phase 3 success in 459 patients and the potential for an IgAN filing path with tiered royalties in the high teens to 20% on Roche net sales. The company also has meaningful commercial momentum from TRYNGOLZA, which is already prescribed to a median 6% of sHTG patients and is expected by physicians to reach 40% by year-end of 2027, while a $4B peak U.S. sales forecast suggests substantial undervaluation. Beyond these catalysts, multiple marketed drugs across rare, cardiovascular, and neurologic diseases support recurring revenue optionality and reduce dependence on any single program.

Ionis Pharmaceuticals is weighed down by commercialization and execution risk, as slower-than-expected TRYNGOLZA uptake, payer restrictions, and gross-to-net pressure could limit near-term revenue growth while launch softness for DAWNZERA, WAINUA PN, or zilganersen would further pressure the portfolio. Its valuation remains highly sensitive to assumptions, with a 9% discount rate and 1% terminal growth rate underpinning the model, yet future royalty streams from partnered programs such as sefaxersen and ulefnersen are excluded, leaving upside uncertain and dependent on successful execution. More broadly, the company faces the classic biotech burden of clinical, regulatory, manufacturing, IP, and financing risk, and higher commercial or R&D spending could delay the 2028 cash-flow break-even target.